GLP3-R

About GLP3-R

GLP3-R is a triple-hormone-receptor agonist, activating the GLP-1, GIP, and glucagon receptors simultaneously. This triple mechanism reduces appetite and increases satiety (GLP-1), supports insulin secretion and energy balance (GIP), and increases energy expenditure (glucagon). In clinical research, GLP3-R produced weight loss comparable to the dual agonist GLP2-T but over a notably shorter period (roughly 48 weeks vs. 72), making it one of the most potent weight-management compounds currently under investigation.

Dosing & Reconstitution Guide

Starting dose:

• If you have never taken any GLP (e.g. semaglutide/Wegovy/Ozempic, tirzepatide/Zepbound/Mounjaro), your initial dose is 2 mg per week.
• If you have previously taken a GLP — no matter how much time has passed — and had one dose increase after starting (e.g. reached 0.50 mg semaglutide or 5 mg tirzepatide), your initial dose is 4 mg per week.

— 10 mg Vial —

Reconstitute: Mix with 1.0 mL (100 units) of bacteriostatic water → 10 mg/mL concentration.
Administration: Subcutaneous injection.
Timing: One dose every 7 days, always on the same day of the week, preferably at a consistent time of day. Fasting is not required.
Recommended syringes: Dosing — 1 mL, 29–30 gauge, 5/16″ tip; Reconstitution — 3 mL, 23–27 gauge, 1″ tip.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.

Schedule: One dose every 7 days.
Cycle Length: Cycling is not mandatory, but to help ensure continuous efficacy, a 4-month cycle followed by a 4-month washout period is recommended.
Goal: Appetite reduction, increased energy expenditure, and accelerated weight loss.

Dose	Syringe (U-100)
2 mg	20 units
4 mg	40 units
6 mg	60 units
8 mg	80 units
10 mg	100 units

— 30 mg Vial —

Reconstitute: Mix with 2.5 mL (250 units) of bacteriostatic water → 12 mg/mL concentration.
Administration: Subcutaneous injection.
Timing: One dose every 7 days, always on the same day of the week, preferably at a consistent time of day. Fasting is not required.
Recommended syringes: Dosing — 1 mL, 29–30 gauge, 5/16″ tip; Reconstitution — 3 mL, 23–27 gauge, 1″ tip.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.

Schedule: One dose every 7 days.
Cycle Length: Cycling is not mandatory, but to help ensure continuous efficacy, a 4-month cycle followed by a 4-month washout period is recommended.
Goal: Appetite reduction, increased energy expenditure, and accelerated weight loss.

Dose	Syringe (U-100)
2 mg	16 units
4 mg	32 units
6 mg	50 units
8 mg	66 units
10 mg	83 units
12 mg	100 units

— 40 mg Vial —

Reconstitute: Mix with 2.5 mL (250 units) of bacteriostatic water → 16 mg/mL concentration.
Administration: Subcutaneous injection.
Timing: One dose every 7 days, always on the same day of the week, preferably at a consistent time of day. Fasting is not required.
Recommended syringes: Dosing — 1 mL, 29–30 gauge, 5/16″ tip; Reconstitution — 3 mL, 23–27 gauge, 1″ tip.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.

Schedule: One dose every 7 days.
Cycle Length: Cycling is not mandatory, but to help ensure continuous efficacy, a 4-month cycle followed by a 4-month washout period is recommended.
Goal: Appetite reduction, increased energy expenditure, and accelerated weight loss.

Dose	Syringe (U-100)
2 mg	12 units
4 mg	25 units
6 mg	38 units
8 mg	50 units
10 mg	62 units
12 mg	75 units

— 60 mg Vial —

Reconstitute: Mix with 2.5 mL (250 units) of bacteriostatic water → 24 mg/mL concentration.
Administration: Subcutaneous injection.
Timing: One dose every 7 days, always on the same day of the week, preferably at a consistent time of day. Fasting is not required.
Recommended syringes: Dosing — 1 mL, 29–30 gauge, 5/16″ tip; Reconstitution — 3 mL, 23–27 gauge, 1″ tip.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.

Schedule: One dose every 7 days.
Cycle Length: Cycling is not mandatory, but to help ensure continuous efficacy, a 4-month cycle followed by a 4-month washout period is recommended.
Goal: Appetite reduction, increased energy expenditure, and accelerated weight loss.

Dose	Syringe (U-100)
2 mg	8 units
4 mg	16 units
6 mg	25 units
8 mg	33 units
10 mg	41 units
12 mg	50 units

— 120 mg Vial —

Reconstitute: Mix with 5.0 mL (500 units) of bacteriostatic water → 24 mg/mL concentration.
Administration: Subcutaneous injection.
Timing: One dose every 7 days, always on the same day of the week, preferably at a consistent time of day. Fasting is not required.
Recommended syringes: Dosing — 1 mL, 29–30 gauge, 5/16″ tip; Reconstitution — 3 mL, 23–27 gauge, 1″ tip.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.

Schedule: One dose every 7 days.
Cycle Length: Cycling is not mandatory, but to help ensure continuous efficacy, a 4-month cycle followed by a 4-month washout period is recommended.
Goal: Appetite reduction, increased energy expenditure, and accelerated weight loss.

Dose	Syringe (U-100)
2 mg	8 units
4 mg	16 units
6 mg	25 units
8 mg	33 units
10 mg	41 units
12 mg	50 units

Benefits

• Triple receptor activation – Simultaneously engages GLP-1, GIP, and glucagon receptors for appetite suppression, improved insulin response, and increased energy expenditure.
• Rapid, substantial weight loss – In phase 2 clinical research, achieved weight loss of up to ~24% of body weight at 48 weeks at the highest dose.
• Improved glycemic control – Supports blood sugar regulation and insulin sensitivity.

Research Sources

Citations for verification. Many studies are animal/in-vitro.

1. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315
2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo- and active-controlled, parallel-group, phase 2 trial (Lancet, 2023).